1. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111–88.
2. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Vol. 139, Circulation. Lippincott Williams and Wilkins; 2019. p. E1082–143.
3. Dias dos Santos Filho Authors R, Maria Lottenberg A, Daniel Magnoni C, Hiroshi Miname M, Soares Lara R, Coordinator S, et al. Fonseca, 7 Raul Dias dos Santos Filho, 11,12 Tales de Carvalho, 13,14,15 Álvaro Avezum Jr., 16 Roberto Esporcatte, 17,18 Bruno Ramos Nascimento, 19 David de Pádua Brasil. Vol. 113. 2019.
4. Faludi A, Izar M, Saraiva J, Chacra A, Bianco H, Afiune Neto A, et al. Atualização da diretriz brasileira de dislipidemias e prevenção da aterosclerose – 2017. Arq Bras Cardiol [Internet]. 2017 [cited 2024 Mar 17];109(1). Available from: http://www.gnresearch.org/doi/10.5935/abc.20170121.
5. Rodríguez-Saldaña J, Padilla-Padilla F, Cardona-Muñoz EG, Romero-Antonio Y, Arguedas-Núñez MM, Sander-Padilla JG, et al. Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients. Cardiol Res Pract. 2022;2022.
6. Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimiba combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. The Lancet. 2022 Jul;400(10349):380–90.
7. Cha JJ, Hong SJ, Kim JH, Lim S, Joo HJ, Park JH, et al. Effect of rosuvastatin 20 mg versus rosuvastatin 5 mg plus ezetimiba on statin side-effects in elderly patients with atherosclerotic cardiovascular disease: Rationale and design of a randomized, controlled SaveSAMS trial. Am Heart J. 2023 Jul 1;261:45–50.
8. Lee SJ, Cha JJ, Choi WG, Lee WS, Jeong JO, Choi S, et al. Moderate-Intensity Statin With Ezetimiba Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2023 Sep 1;8(9):853.
9. C. Thambiah S, Lai LC. Diabetic dyslipidaemia. Pract Lab Med. 2021 Aug;26:e00248.
10. Izar MC de O, Fonseca FAH, Faludi AÁ, Araújo DB de, Valente F, Bertoluci M. Manejo do risco cardiovascular: dislipidemia. In: Diretriz Oficial da Sociedade Brasileira de Diabetes. Conectando Pessoas; 2022.
11. Lucero D, Wolska A, Aligabi Z, Turecamo S, Remaley AT. Lipoprotein Assessment in the twenty-first Century. Endocrinol Metab Clin North Am. 2022 Sep;51(3):459–81.
12. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimiba Added to Statin Therapy after Acute Coronary Syndromes. New England Journal of Medicine. 2015 Jun 18;372(25):2387–97.
13. Nakamura A, Sato K, Kanazawa M, Kondo M, Endo H, Takahashi T, et al. Impact of decreased insulin resistance by ezetimiba on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease. Heart Vessels. 2019 Jun 14;34(6):916–25.
14. Han JH, Joung KH, Lee JC, Kim OS, Choung S, Kim JM, et al. Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimiba Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus. Diabetes Metab J. 2024 Jan 1;48(1):112–21.
15. Wu H, Shang H, Wu J. Effect of ezetimiba on glycemic control: a systematic review and meta-analysis of randomized controlled trials. Endocrine. 2018 May 3;60(2):229–39.
